IBB News and Press, iShares Biotechnology ETF From 01/07/24

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2024-01-06 08:15:00 ET Summary Global equity markets experienced a surge in 2023 driven by economic growth and investor confidence. US equity returns exceeded expectations despite concerns about higher rates, inflation, and geopolitical tension. In 2024, investors should focus...

2024-01-05 11:01:47 ET Summary In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding factor for why so few stocks, think Magnificent 7, re...

2023-12-25 10:03:02 ET Summary I discuss my investment and trading strategies before and after March 2022. I highlight the importance of trade income, capital gains, dividend collection, and tax harvesting in my investment approach. I want to see the Bull Plateau (or Bear-Mark...

2023-12-21 14:39:55 ET More on iShares Biotechnology ETF IBB: Technicals And Risk Metrics Point To Lower Prices (Technical Analysis) IBB: Targeting A Buy Point Heading Into Year-End Biotechs rally with gene editing stocks among notable gainers Citi turns caut...

2023-12-21 08:25:00 ET Summary Given strong recent market returns and another wave of capital inflows, the backdrop is probably not enough to lead to strong tactical performance from risk assets. The US has a more favorable demographic trend; its working-age population is expected...

2023-12-20 06:19:00 ET Summary Can the Magnificent 7 continue to rally into 2024? How the Magnificent 7's rise compares to the dot-com bubble. Why the rise in tech stocks highlights shortcomings for the markets. The rise of the Magnificent 7 tech stocks has been a ke...

2023-12-14 13:22:45 ET Summary The Federal Reserve's Open Market Committee offered the possibility of three rate cuts next year, driving stock market indexes to new highs. The Fed's outlook has pivoted towards market expectations, with a median range of 4.50% to 4.75% interest rat...

2023-12-14 10:03:54 ET Summary Biotech stocks have experienced a significant decline since February 2021, but better times are ahead due to several tailwinds. Scientific and medical breakthroughs, such as cell therapies, genetic medicines, and incretins in obesity, are creating la...

2023-12-11 08:11:03 ET Summary US sectoral flows for November 2023 analyzed for impact on markets in December. Whopping $363 billion private sector surplus pointing to better markets in December. Fiscal flows expected to continue funding the economy and feeding the bull market...